109 related articles for article (PubMed ID: 2355740)
1. Use of rhodamine 123 in the treatment of the Pollard III rat prostate adenocarcinoma.
Arcadi JA
J Surg Oncol; 1990 Jun; 44(2):103-8. PubMed ID: 2355740
[TBL] [Abstract][Full Text] [Related]
2. Rhodamine-123 as effective agent in rat prostate tumor R3327-H. Preliminary report.
Arcadi JA
Urology; 1986 Dec; 28(6):501-3. PubMed ID: 3787924
[TBL] [Abstract][Full Text] [Related]
3. Anticarcinoma activity of rhodamine 123 against a murine renal adenocarcinoma.
Herr HW; Huffman JL; Huryk R; Heston WD; Melamed MR; Whitmore WF
Cancer Res; 1988 Apr; 48(8):2061-3. PubMed ID: 3349477
[TBL] [Abstract][Full Text] [Related]
4. The effect of rhodamine-123 on 3 prostate tumors from the rat.
Arcadi JA
J Urol; 1998 Dec; 160(6 Pt 2):2402-6. PubMed ID: 9817392
[TBL] [Abstract][Full Text] [Related]
5. [Hormonal treatment in cancer of the prostate].
Boccon-Gibod L
Rev Prat; 1987 Feb; 37(7):386-90. PubMed ID: 3823774
[No Abstract] [Full Text] [Related]
6. Studies of rhodamine-123: effect on rat prostate cancer and human prostate cancer cells in vitro.
Arcadi JA; Narayan KS; Techy G; Ng CP; Saroufeem RM; Jones LW
J Surg Oncol; 1995 Jun; 59(2):86-92; discussion 92-3. PubMed ID: 7776658
[TBL] [Abstract][Full Text] [Related]
7. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
8. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye.
Bernal SD; Lampidis TJ; McIsaac RM; Chen LB
Science; 1983 Oct; 222(4620):169-72. PubMed ID: 6623064
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition by diethylstilbestrol and relapse of the Noble rat prostatic tumor.
Wakisaka M; Drury RE; Kadohama N
Hinyokika Kiyo; 1988 Jan; 34(1):107-15. PubMed ID: 3376790
[TBL] [Abstract][Full Text] [Related]
10. Interstitial laser photochemotherapy of rhodamine-123-sensitized rat glioma.
Powers SK; Beckman WC; Brown JT; Kolpack LC
J Neurosurg; 1987 Dec; 67(6):889-94. PubMed ID: 3681427
[TBL] [Abstract][Full Text] [Related]
11. Laser photochemotherapy of rhodamine-123 sensitized human glioma cells in vitro.
Powers SK; Pribil S; Gillespie GY; Watkins PJ
J Neurosurg; 1986 Jun; 64(6):918-23. PubMed ID: 3701443
[TBL] [Abstract][Full Text] [Related]
12. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.
Theyer G; Schirmböck M; Thalhammer T; Sherwood ER; Baumgartner G; Hamilton G
J Urol; 1993 Nov; 150(5 Pt 1):1544-7. PubMed ID: 8105110
[TBL] [Abstract][Full Text] [Related]
13. Phototherapy with the argon laser on human melanoma cells "sensitized" with rhodamine-123: a new method for tumor growth inhibition.
Castro DJ; Saxton RE; Fetterman HR; Castro DJ; Ward PH
Laryngoscope; 1988 Apr; 98(4):369-76. PubMed ID: 3352433
[TBL] [Abstract][Full Text] [Related]
14. Rhodamine-123 as a new photochemosensitizing agent with the argon laser: "nonthermal" and thermal effects on human squamous carcinoma cells in vitro.
Castro DJ; Saxton RE; Fetterman HR; Castro DJ; Ward PH
Laryngoscope; 1987 May; 97(5):554-61. PubMed ID: 3573900
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of nonhormonal cytotoxic chemotherapy in the Nb rat (Pr-90) prostatic carcinoma.
Drago JR; Goldman LB
Cancer; 1980 Feb; 45(4):757-63. PubMed ID: 7357493
[TBL] [Abstract][Full Text] [Related]
16. Phototherapy with argon lasers and Rhodamine-123 for tumor eradication.
Castro DJ; Saxton RE; Fetterman HR; Castro DJ; Ward PH
Otolaryngol Head Neck Surg; 1988 Jun; 98(6):581-8. PubMed ID: 3138616
[TBL] [Abstract][Full Text] [Related]
17. A pilot trial of chemohormonal therapy for metastatic prostate carcinoma.
Dawson NA; Wilding G; Weiss RB; McLeod DG; Linehan WM; Frank JA; Jacob JL; Gelmann EP
Cancer; 1992 Jan; 69(1):213-8. PubMed ID: 1727665
[TBL] [Abstract][Full Text] [Related]
18. Rhodamine-123: therapy for hormone refractory prostate cancer, a phase I clinical trial.
Jones LW; Narayan KS; Shapiro CE; Sweatman TW
J Chemother; 2005 Aug; 17(4):435-40. PubMed ID: 16167524
[TBL] [Abstract][Full Text] [Related]
19. [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
Labrie F; Dupont A; Bélanger A; Lacourcière Y; Monfette JE; Monfette G
Ann Urol (Paris); 1986; 20(2):98-106. PubMed ID: 2940959
[TBL] [Abstract][Full Text] [Related]
20. Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas.
Dijkman GA; Van Moorselaar RJ; Van Ginckel R; Van Stratum P; Wouters L; Debruyne FM; Schalken JA; de Coster R
J Urol; 1994 Jan; 151(1):217-22. PubMed ID: 8254818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
